|
注册号: Registration number: |
ChiCTR2500104780 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-23 17:05:15 |
|
注册时间: Date of Registration: |
2025-06-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
心血管疾病患者病情变化预警模型的构建与验证 |
|
Public title: |
Construction and validation of an early warning model of disease change in patients with cardiovascular disease |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
心血管疾病患者病情变化预警模型的构建与验证 |
|
Scientific title: |
Construction and validation of an early warning model of disease change in patients with cardiovascular disease |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张雨婷 |
研究负责人: |
陈亚丹 |
|
Applicant: |
Zhang Yuting |
Study leader: |
Chen Yadan |
|
申请注册联系人电话: Applicant telephone: |
+1 520 590 3708 |
研究负责人电话:
Study leader's |
+1 820 595 7211 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2964830688@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
xiyuan85@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省福州市闽侯县学府北路1号 |
研究负责人通讯地址: |
福建省厦门市思明区镇海路55号 |
|
Applicant address: |
No. 1, Xuefu North Road, Minhou County, Fuzhou City, Fujian Province |
Study leader's address: |
No. 55, Zhenhai Road, Siming District, Xiamen City, Fujian Province |
|
申请注册联系人邮政编码: Applicant postcode: |
350122 |
研究负责人邮政编码: Study leader's postcode: |
350122 |
|
申请人所在单位: |
福建医科大学 |
||
|
Applicant's institution: |
Fujian Medical University |
||
|
研究负责人所在单位: |
厦门大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Hospital of Xiamen University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2025]科研伦审字(106)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
厦门大学附属第一医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Research Ethics Committee, The First Affiliated Hospital of Xiamen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-06-20 00:00:00 | ||
|
伦理委员会联系人: |
马永慧,李津 |
||
|
Contact Name of the ethic committee: |
Ma Yonghui, Li Jin |
||
|
伦理委员会联系地址: |
福建省厦门市思明区镇海路55号 |
||
|
Contact Address of the ethic committee: |
No. 55, Zhenhai Road, Siming District, Xiamen City, Fujian Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 592137569 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
xdfyec@sina.com |
|
研究实施负责(组长)单位: |
厦门大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Hospital of Xiamen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省厦门市思明区镇海路55号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Clinical Research Ethics Committee, The First Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, China. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
厦门市卫生健康委员会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Xiamen Municipal Health Commission |
||||||||||||||||||||||
|
研究疾病: |
心血管疾病 |
||||||||||||||||||||||
|
Target disease: |
cardiovascular disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例研究 |
||||||||||||||||||||||
|
Study design: |
Case study |
||||||||||||||||||||||
|
研究目的: |
1.通过分析可能导致心血管病患者发生病情变化的因素,提高医护人员对患者病情变化的早期识别能力,以便及时采取干预措施; 2.构建一个科学、全面且完善的适用于心血管临床工作的心血管疾病患者病情变化预警评分模型,以弥补临床上以经验性判断病情变化的不足,优化资源分配。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. By analyzing the factors that may lead to the changes in the condition of patients with cardiovascular disease, improve the ability of medical staff to identify the changes in the patient's condition in an early manner, so as to take timely interventions; 2. Construct a scientific, comprehensive and complete early warning scoring model for patients with cardiovascular diseases suitable for cardiovascular clinical work, so as to make up for the lack of empirical judgment of disease changes in clinical practice and optimize resource allocation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.资料不全者; 2.非心血管疾病导致的病情变化,包括感染(如肺部感染、泌尿系感染)、呼吸系统疾病(如ARDS)、消化系统疾病(如急性胰腺炎、消化道出血)、神经系统疾病(如脑出血、蛛网膜下腔出血)、内分泌疾病(如糖尿病酮症酸中毒)、创伤及其他系统疾病(如骨折、急性肾衰竭)等引起的病情变化; 3.2022年11月至2023年5月数据(因此期大量新冠病毒患者住院,CCU 纳入医院综合管理,可能影响到收治病种). |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Those with incomplete information; 2. Changes in the condition caused by non-cardiovascular diseases, including infections (such as lung infections, urinary tract infections), respiratory diseases (such as ARDS), digestive diseases (such as acute pancreatitis, gastrointestinal bleeding), neurological diseases (such as cerebral hemorrhage, subarachnoid hemorrhage), endocrine diseases (such as diabetic ketoacidosis), trauma and other systemic diseases (such as fractures, acute renal failure), etc.; 3. Data from November 2022 to May 2023 (due to the hospitalization of a large number of new coronavirus patients during this period, CCU is included in the comprehensive management of hospitals, which may affect the types of diseases admitted). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-27 00:00:00至 To 2026-06-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-06-27 00:00:00 至 To 2026-06-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |